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to alleviate pain. In contrast, other research (Mantovani, et al.,
2005) suggests greater importance of perceived viral safety
among both physicians and pharmacists relative to patients.
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OBJECTIVE: Assess the effects of tramadol ER once daily
versus placebo in patients with moderate to moderately severe
chronic pain due to osteoarthritis of the knee or hip.
METHODS: Data for this post-hoc analysis were from a
12-week, randomized, double-blind, placebo-controlled, once-
daily ﬁxed dose-study of tramadol ER (100 mg–300 mg).
Patients completed the WOMAC questionnaire at baseline and
weeks 1, 2, 3, 6, 9 and 12. Items in each WOMAC
subscale—pain (5-items), physical functioning (17-items) and
stiffness (2-items) were combined and normalized from 0-to
100. The minimum clinically important difference (MCID) set
at ten points improvement was determined from the literature.
Mean subscale scores, percent mean change from baseline and
the proportion of patients achieving a MCID at week 1 and 12
were assessed. RESULTS: A total of 809 patients were analyzed
(604-tramadol ER; 205-placebo). Both cohorts had similar
demographic and clinical characteristics at baseline. At week 1,
mean change in WOMAC global and subscale scores from
baseline for tramadol ER and placebo ranged from 12–16 and
7–10 points, respectively. Signiﬁcantly higher proportion of tra-
madol ER treated patients achieved MCID versus placebo
(p < 0.05) as early as week 1 except in the stiffness subscale. By
week 12, mean change for each subscale and total WOMAC
global score for tramadol ER treated patients were signiﬁcantly
greater versus placebo (p < 0.01), however, only higher doses
(200–300 mg) of tramadol ER treated patients achieved MCID
versus placebo (p < 0.01)On pain subscale, signiﬁcantly higher
proportion of patients treated with tramadol ER 100 mg
achieved MCID versus placebo at week 1 and 12 (p < 0.05).
CONCLUSION: This analysis showed that treatment with tra-
madol ER in patients with chronic pain extended to improve-
ments in physical function and stiffness as demonstrated by
achieving MCID in all WOMAC scores.
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OBJECTIVE: To assess the psychometric properties of the Power
of Food Scale (PFS) in diverse populations of obese and non-
obese individuals. METHODS: Data were obtained from adults
in a clinical trial for a weight management drug (n = 1739; mean
body mass index [BMI] [SD] = 38.6 [6.7]) and a web-based
survey (n = 1275; overweight and obese [BMI 27–76 kg/m2] and
non-obese [BMI 18–27 kg/m2]). Exploratory and conﬁrmatory
factor analyses were employed to discover the structure of PFS
using the clinical data. The model developed was then tested
using data from the web-based survey. The relationship between
PFS domains and BMI was also examined. Logistic regression
was used in the web-based survey to evaluate the association
between obese status and PFS scores. RESULTS: Psychometric
assessment of data from the clinical study indicated that the scale
was best represented by a 3-factor, 2nd-order model—three
domains and a composite domain (average of the three
domains)—which was conﬁrmed within the web-based survey
(Bentler’s Comparative Fit Index: 0.92 and 0.91, respectively).
Cronbach’s alpha for both data sets were high, ranging from
0.81–0.94 (three domains and a composite domain score). The
relationships between BMI and each domain were subtle and
approximately linear. An increase of one point in a PFS domain
score increased the odds of being obese by 1.6–2.4 times
(depending on the domain; domain scores range from 1 to 5).
CONCLUSION: The structure of PFS is represented by a 3
factor, 2nd-order model with three domains (Food Available,
Food Present, and Food Tasted) and a composite of them. This
structure has high internal consistency and reliability, relates to
BMI, and distinguishes between obese and non-obese subjects.
The data indicate that the PFS can be used to evaluate the effects
of treatment on patient perception of the power of food in trials
of obese patients.
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OBJECTIVE: Prior to use in an international study collecting
data from haemophiliacs, the Haemo-QoL and Haem-A-QoL
underwent linguistic validation in 17 languages. Whilst the origi-
nal Haemo-QoL was developed in British English, the Haem-A-
QoL had been developed in Italian. For the purposes of linguistic
validation, an English version of the latter was used as a basis for
the translations. Seven distinct versions exist: an adult form
(Haem-A-QoL) and child self-report and parent proxy versions
(Haemo-QoL) for 3 distinct age groups (4–7, 8–12, 13–16 years).
A rigorous methodology was required to ensure conceptual
equivalence and cultural relevance across different languages.
METHODS: For languages where no translation existed, the
process was conducted by a specialist in each target country
using the following standardized methodology: 1) two forward
translations by professional translators, native speakers of the
target language and ﬂuent in English; 2) comparison and recon-
ciliation of the translations by the specialist in the target country;
3) backward translation by a native English speaker; 4) compari-
son of source and backward version; 5) review by the developer
for a selection of languages; creation of the different forms of the
instrument; and 6) review by a clinician. Existing translations
were integrated into the process as appropriate. RESULTS:
Besides the challenge of ensuring conceptual equivalence with the
original and cultural appropriateness, the translation process
revealed two additional difﬁculties. When translating an expres-
sion, appropriate terms had to be found for each age group
whilst maintaining consistency across all versions of the same
language. CONCLUSION: The language versions of Haemo-
QoL and Haem-A-QoL were established according to a rigorous
translation methodology aiming to ensure conceptual equiva-
lence across different language versions to facilitate international
comparison and pooling of data. The linguistic validation
process as a whole supports the advantage of integrating inter-
national feedback on concepts and wording before a question-
naire is ﬁnalized.
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